Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
This study is not yet open for participant recruitment.
Verified September 2011 by Shanghai Sixth People's Hospital
Study NCT01417767   Information provided by Shanghai Sixth People's Hospital

First Received on August 15, 2011.   Last Updated on September 1, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Precancerous Conditions
Interventions listed in this trial
CHG regimen
5-aza-deoxycytidine
Additional drug interventions recognized in this trial
Azacitidine
Cytarabine
Decitabine
Homoharringtonine
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Xiao Li


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services